{"pmid":32307717,"title":"COVID-19 diagnosis does not rule out other concomitant diseases.","text":["COVID-19 diagnosis does not rule out other concomitant diseases.","we read with interest the editorial by Prof. Ioannidis [1], expressing concern on the exaggerated information regarding the ongoing pandemic of COVID-19 [2]. Certainly, Clinicians worldwide are facing new and enormous challenges when considering patients with suspected COVID-19; unfortunately, while the situation in China and Eastern Asia has shown a reduction in the number of new diagnosis in the last couple of weeks, the spread of SARS-CoV-2 infections in Europe, and in particular in Italy, has seen a dramatic increase, with more than 160'000 cases and '20'000 deaths as of April 14, 2020 [3]. Even in this pandemic phase, however, it should not be forgotten that the diagnosis of COVID-19 does not imply the exclusion of other concomitant diseases.","Eur J Clin Invest","Borghetti, Alberto","Ciccullo, Arturo","Visconti, Elena","Tamburrini, Enrica","Di Giambenedetto, Simona","32307717"],"abstract":["we read with interest the editorial by Prof. Ioannidis [1], expressing concern on the exaggerated information regarding the ongoing pandemic of COVID-19 [2]. Certainly, Clinicians worldwide are facing new and enormous challenges when considering patients with suspected COVID-19; unfortunately, while the situation in China and Eastern Asia has shown a reduction in the number of new diagnosis in the last couple of weeks, the spread of SARS-CoV-2 infections in Europe, and in particular in Italy, has seen a dramatic increase, with more than 160'000 cases and '20'000 deaths as of April 14, 2020 [3]. Even in this pandemic phase, however, it should not be forgotten that the diagnosis of COVID-19 does not imply the exclusion of other concomitant diseases."],"journal":"Eur J Clin Invest","authors":["Borghetti, Alberto","Ciccullo, Arturo","Visconti, Elena","Tamburrini, Enrica","Di Giambenedetto, Simona"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307717","week":"202017|Apr 20 - Apr 26","doi":"10.1111/eci.13241","keywords":["covid-19","infectious diseases","sars-cov-2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["China","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"_version_":1664632501381890048,"score":8.518259,"similar":[{"pmid":32294236,"title":"Exaggerated information and COVID-19 outbreak.","text":["Exaggerated information and COVID-19 outbreak.","We read the article on \"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures\" with a great interest [1]. Ioannidis noted that \"It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions [1].\"","Eur J Clin Invest","Sriwijitalai, Won","Wiwanitkit, Viroj","32294236"],"abstract":["We read the article on \"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures\" with a great interest [1]. Ioannidis noted that \"It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions [1].\""],"journal":"Eur J Clin Invest","authors":["Sriwijitalai, Won","Wiwanitkit, Viroj"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294236","week":"202016|Apr 13 - Apr 19","doi":"10.1111/eci.13226","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664636192562348032,"score":173.74469},{"pmid":32281052,"title":"Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","text":["Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.","Stem Cell Rev Rep","Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza","32281052"],"abstract":["\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing."],"journal":"Stem Cell Rev Rep","authors":["Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281052","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s12015-020-09973-w","keywords":["covid-19","clinical trials","coronavirus","immunomodulatory","mesenchymal stem cell","stem cell therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636704096518144,"score":156.64351},{"pmid":32202659,"title":"Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.","text":["Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures.","The evolving coronavirus disease 2019 (COVID-19) pandemic(1) is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. The challenge is compounded, however, by exaggerated information. This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions.","Eur J Clin Invest","Ioannidis, John P A","32202659"],"abstract":["The evolving coronavirus disease 2019 (COVID-19) pandemic(1) is certainly cause for concern. Proper communication and optimal decision-making is an ongoing challenge, as data evolve. The challenge is compounded, however, by exaggerated information. This can lead to inappropriate actions. It is important to differentiate promptly the true epidemic from an epidemic of false claims and potentially harmful actions."],"journal":"Eur J Clin Invest","authors":["Ioannidis, John P A"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32202659","week":"202013|Mar 23 - Mar 29","doi":"10.1111/eci.13223","source":"PubMed","weight":0,"_version_":1664639760390422529,"score":145.62312},{"pmid":32304119,"title":"Tracheostomy during COV-SARS-CoV-2 pandemic: Recommendations from the New York Head and Neck Society.","text":["Tracheostomy during COV-SARS-CoV-2 pandemic: Recommendations from the New York Head and Neck Society.","The rapid spread of SARS-CoV-2 in 2019 and 2020 has resulted in a worldwide pandemic characterized by severe pulmonary inflammation, effusions, and rapid respiratory compromise. The result of this pandemic is a large and increasing number of patients requiring endotracheal intubation and prolonged ventilator support. The rapid rise in endotracheal intubations coupled with prolonged ventilation requirements will certainly lead to an increase in tracheostomy procedures in the coming weeks and months. Performing tracheostomy in the setting of active COV-SARS-CoV-2, when necessary, poses a unique situation, with unique risks and benefits for both the patient and the health care providers. The New York Head and Neck Society has collaborated on this document to provide guidance on the performance of tracheostomies during the SARS-CoV-2 pandemic.","Head Neck","Miles, Brett A","Schiff, Bradley","Ganly, Ian","Ow, Thomas","Cohen, Erik","Genden, Eric","Culliney, Bruce","Mehrotra, Bhoomi","Savona, Steven","Wong, Richard J","Haigentz, Missak","Caruana, Salvatore","Givi, Babak","Patel, Kepal","Hu, Kenneth","32304119"],"abstract":["The rapid spread of SARS-CoV-2 in 2019 and 2020 has resulted in a worldwide pandemic characterized by severe pulmonary inflammation, effusions, and rapid respiratory compromise. The result of this pandemic is a large and increasing number of patients requiring endotracheal intubation and prolonged ventilator support. The rapid rise in endotracheal intubations coupled with prolonged ventilation requirements will certainly lead to an increase in tracheostomy procedures in the coming weeks and months. Performing tracheostomy in the setting of active COV-SARS-CoV-2, when necessary, poses a unique situation, with unique risks and benefits for both the patient and the health care providers. The New York Head and Neck Society has collaborated on this document to provide guidance on the performance of tracheostomies during the SARS-CoV-2 pandemic."],"journal":"Head Neck","authors":["Miles, Brett A","Schiff, Bradley","Ganly, Ian","Ow, Thomas","Cohen, Erik","Genden, Eric","Culliney, Bruce","Mehrotra, Bhoomi","Savona, Steven","Wong, Richard J","Haigentz, Missak","Caruana, Salvatore","Givi, Babak","Patel, Kepal","Hu, Kenneth"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304119","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hed.26166","keywords":["covid19","sars-cov-2","airway","tracheal stenosis","tracheostomy"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664632934655590400,"score":142.83427},{"pmid":32313828,"pmcid":"PMC7166304","title":"A \"One-Health\" approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy.","text":["A \"One-Health\" approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy.","The current pandemic is caused by a novel coronavirus (CoV) called SARS-CoV-2 (species Severe acute respiratory syndrome-related coronavirus, subgenus Sarbecovirus, genus Betacoronavirus, family Coronaviridae). In Italy, up to the 2nd of April 2020, overall 139,422 confirmed cases and 17,669 deaths have been notified, while 26,491 people have recovered. Besides the overloading of hospitals, another issue to face was the capacity to perform thousands of tests per day. In this perspective, to support the National Health Care System and to minimize the impact of this rapidly spreading virus, the Italian Ministry of Health involved the Istituti Zooprofilattici Sperimentali (IZSs), Veterinary Public Health Institutes, in the diagnosis of SARS-CoV-2 by testing human samples. IZSAM, is currently testing more than 600 samples per day and WGS from positive samples. Sequence analysis of these samples suggested that outbreaks in Abruzzo region may be related to outbreaks of northern Italy and northern Europe, these latter as for the presence of mutations in the N protein. CoVs, and related diseases, are well known to veterinarians since decades. The experience that veterinarians operating within the Public health system gained in the control and characterization of previous health issues of livestock and poultry including avian flu, bluetongue, foot and mouth disease, responsible for huge economic losses, is certainly of great help to minimize the impact of this global crisis.","One Health","Lorusso, Alessio","Calistri, Paolo","Mercante, Maria Teresa","Monaco, Federica","Portanti, Ottavio","Marcacci, Maurilia","Camma, Cesare","Rinaldi, Antonio","Mangone, Iolanda","Di Pasquale, Adriano","Iommarini, Marino","Mattucci, Maria","Fazii, Paolo","Tarquini, Pierluigi","Mariani, Rinalda","Grimaldi, Alessandro","Morelli, Daniela","Migliorati, Giacomo","Savini, Giovanni","Borrello, Silvio","D'Alterio, Nicola","32313828"],"abstract":["The current pandemic is caused by a novel coronavirus (CoV) called SARS-CoV-2 (species Severe acute respiratory syndrome-related coronavirus, subgenus Sarbecovirus, genus Betacoronavirus, family Coronaviridae). In Italy, up to the 2nd of April 2020, overall 139,422 confirmed cases and 17,669 deaths have been notified, while 26,491 people have recovered. Besides the overloading of hospitals, another issue to face was the capacity to perform thousands of tests per day. In this perspective, to support the National Health Care System and to minimize the impact of this rapidly spreading virus, the Italian Ministry of Health involved the Istituti Zooprofilattici Sperimentali (IZSs), Veterinary Public Health Institutes, in the diagnosis of SARS-CoV-2 by testing human samples. IZSAM, is currently testing more than 600 samples per day and WGS from positive samples. Sequence analysis of these samples suggested that outbreaks in Abruzzo region may be related to outbreaks of northern Italy and northern Europe, these latter as for the presence of mutations in the N protein. CoVs, and related diseases, are well known to veterinarians since decades. The experience that veterinarians operating within the Public health system gained in the control and characterization of previous health issues of livestock and poultry including avian flu, bluetongue, foot and mouth disease, responsible for huge economic losses, is certainly of great help to minimize the impact of this global crisis."],"journal":"One Health","authors":["Lorusso, Alessio","Calistri, Paolo","Mercante, Maria Teresa","Monaco, Federica","Portanti, Ottavio","Marcacci, Maurilia","Camma, Cesare","Rinaldi, Antonio","Mangone, Iolanda","Di Pasquale, Adriano","Iommarini, Marino","Mattucci, Maria","Fazii, Paolo","Tarquini, Pierluigi","Mariani, Rinalda","Grimaldi, Alessandro","Morelli, Daniela","Migliorati, Giacomo","Savini, Giovanni","Borrello, Silvio","D'Alterio, Nicola"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313828","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.onehlt.2020.100135","keywords":["covid-19","molecular characterization","mutations","next generation sequencing","one health","sars-cov-2","variants","veterinarians"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Sarbecovirus","Italy","Italy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664714520145166336,"score":130.9968}]}